Attorney Docket:

7640-X04-017

MAR 0 9 2005

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Appln. of:

Israel VLODAVSKY et al

**Group Art Unit:** 

1614

Appln. No.:

10/789,428

Filed:

February 27, 2004

For:

EOSINOPHIL MAJOR BASIC PROTEIN AS A NATURAL

HEPARANASE-INHIBITING PROTEIN, COMPOSITIONS, METHODS

AND USES THEREOF

# INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Dear Sir:

Submitted herewith are:

- (1) Form: PTO/SB/08a and PTO/SB/08b; and
- (2) Copies of the publications cited in said PTO/SB/08a and PTO/SB/08b.

It is requested that an initialed copy of the form PTO/SB/08a be returned to indicate that the publications listed therein have been considered and made of record.

A fee of \$180 is enclosed for filing an Information Disclosure Statement at this stage of prosecution. Enclosed is a Form PTO-2028 (Credit Card Form). If any deficiencies in fees are due, please charge Deposit Account 500601 for such sum (Docket No. 7640-X04-017).

02 FG81805

\$60,00 \$2

Respectfully submitted,

Martin Fleit, Reg. #16,900

00 %; Martin Fleit

FLEIT KAIN GIBBONS GUTMAN BONGINI & BIANCO, P.L.

601 Brickell Key Drive Suite 404

Miami, Florida 33131

Tel: 305-416-4490; Fax: 305-416-4489

e-mail: MFleit@FocusOnIP.com



**Attorney Docket No:** 

7640-X04-017

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:

Israel VLODAVSKY, Gerald J. GLEICH and Francesca

LEVI-SCHAFFER

Serial No.:

10/789,428

Group Art Unit: 1614

Filed:

February 27, 2004

Examiner:

Title:

EOSINOPHIL MAJOR BASIC PROTEIN AS A NATURAL HEPARANASE-INHIBITING PROTEIN, COMPOSITIONS,

METHODS AND USES TEHEOF

#### CERTIFICATE OF EXPRESS MAILING

#### **PATENTS**

EXPRESS "Express Mail" Mailing Label number EV 674788887 US Date of March 9, 2005

I hereby certify that the attached paper(s) or fee(s) is/are being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated above and is addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

**ESTEFANIA BELAUNDE** 

(Typed or printed name of person mailing paper or fee)

Approved for use through 05/31/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Ibstitute for form 1449A/PTO

STEM & THE

Sheet

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete II Known					
Application Number	10/789,428				
Filing Date	February 27, 2004				
First Named Inventor	Israel VLODAVSKY				
Art Unit	1614				
Examiner Name					
Attorney Docket Number	7640-Y04-017				

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
	†	US-				
	<del> </del> -	US-				
		US-		· · · · · · · · · · · · · · · · · · ·		
	-	US-				
		US-				
		US-				
		US-				
	<u> </u>	US-			- 1 111 - 111 - 118 - 11	
	ļ ·	ŪS-		* · · · · · · · · · · · · · · · · · · ·		
	ļ	US-				
	1	US-				
		US-				
	İ	US-		·		
	1	US-				
		US-				
		US-				
	†	US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰	
••••••		WO 02/060374 A2	08-08-2002	Insight Strategy & Marketing Ltd			
***************************************					•	┝	
					***************************************		

Examiner			Date	
Signature			Considered	
		_	. I	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.usp.to.gov.or/">www.usp.to.gov.or/</a> of MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO Complete if Known **Application Number** 10/789,428 INFORMATION DISCLOSURE Filing Date February 27, 2004 STATEMENT BY APPLICANT First Named Inventor Israel VLODAVSKY Art Unit 1614 (Use as many sheets as necessary) Examiner Name Sheet Attorney Docket Number 2 of 7640-X04-017

NON PATENT LITERATURE DOCUMENTS						
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	1	Bernard, D. et al., J. Invest. Dermatol. 117:1266-73 (2001)				
	2	Carlson, M.G. et al., J, Iminunol. 134:1875-9 (1985)				
	3	Chekhonin V.P. et al., Vopr, Med. Khim. 46:54963 (2000) (abstract only)				
	4	Dempsey, L.A. et al., Trends Biochem. Sci. 25:349-51 (2000)				
	5	Fairbanks, M.B. et al., J. Biol. Chem. 274:29587-29590 (1999)				
	6	Friedmann, Y. et al., Am. J. Pathol. 157:1167-1175 (2000)				
•••••••	7	Gleich, G.J., Allergy Clin. Immunol. 105:651-663 (2000)				
	8	Gleich, G.J. J. et al., Clin. Invest 57:633-40 (1976)				
••••••	9	Goldshmidt, O. et al., Exp. Cell Res. 281:50-62 (2002)				
•••••	10	Goldshmidt, O. et al., J. Biol. Chem. 276:29178-87 (2001)				

Examiner	Date	
Signature	 Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO Complete if Known **Application Number** 10/789,428 INFORMATION DISCLOSURE Filing Date February 27, 2004 STATEMENT BY APPLICANT First Named Inventor Israel VLODAVSKY Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number of 3 7640-X04-017

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	11	Goldshmidt, O. et al., Proc. Natl. Acad. Sci. USA 99:10031-6 (2002)				
	12	Gong et al. J. Biol. Chem. 278:35152-35158 (2003)				
	13	Hallsworth, M.P. et al., Am. J. Respir. Cell Mol. Biol. 19:910-9 (1998)				
	14	Hoenstein R. et al., Cell. Immunol. 210:116-24 (2001)				
	15	Hulett, M.D. et al., Nat. Med. 5:803-809 (1999)				
	16	Kawase, Y. J. Antibiotics 49:61-64 (1995)				
***************************************	17	Kuhry, J.G. et al., Agents Actions 16:109-12 (1985)				
	18	Levi-Schaffer, F. et al., Proc. Natl. Acad. Sci. USA 96:9660-5 (1999)				
	19	Lider, O. J. et al., Clin. Invest. 83:752-756 (1989)				
	20	Mallorqui-Fernandez, G. et al., J, Mol. Biol. 300:1297-307 (2000)				

4				i .	$\overline{}$
1					
1	Examiner		Date	l .	
ı	Signature		Considered	ĺ	}

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO Complete if Known **Application Number** 10/789,428 INFORMATION DISCLOSURE **Filing Date** February 27, 2004 STATEMENT BY APPLICANT First Named Inventor Israel VLODAVSKY Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Sheet of Attorney Docket Number 4 7640-X04-017

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>			
	21	Matzner, Y. et al., J. Clin. Invest. 76:1306-13 (1985)				
	22	Mollinedo, F. et al., Biochem. J. 327:917-923 (1997)				
	23	Nadav, L. et al., J. Cell Sci. 115(10):2179-87 (2002)				
	24	Nagler, A. et al., Arteriosclerosis, Thrombosis & Vascular Biol. 17:194-202 (1997)				
	25	Nakajima, M. et al., J. Cell. Biochem. 36:157-163 (1988)				
	26	Nakajima, M. et al., J. Biol. Chem, 266:9661-9666 (1991)				
	27	Nishimura, Y. et. al., O. Antibiot, 47:101407 (1994)				
	28	O'Donnell, M.C. et al., J. Exp. Med. 157:1981-91 (1983)				
	29	Parish, C.R. et al., Biochim. Biophys. Acta. 1471:M99-M108 (2001)				
	30	Parish, C.R, et al,, Cancer Res. 59:3433-3441 (1999)				

- 1	ſ		1
	Examiner	Date	
	Signature	Considered	J

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO Complete if Known **Application Number** 10/789,428 INFORMATION DISCLOSURE Filing Date February 27, 2004 STATEMENT BY APPLICANT First Named Inventor Israel VLODAVSKY Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number of 7640-X04-017

		NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	31	Parish, C.R. et al., Int. J. Cancer 40:511-518 (1987)	
	32	Pikas, D.S, et al., J. Biol. Chem. 273:18770-18777 (1998)	
	33	Samoszuk M. Histol Histopathol. 12:807-12 (1997) (Abstract only)	
	34	Shteper, P.J. et al., Oncogene 22:7737-7749 (2003)	
	35	Simon H-U. et al., J. Immunol. 165:4069-75 (2000)	
	36	Slifman, N. R. et al., J. Immunol. 137:2913-291.7 (1986)	
	37	Solomon, A. et al., Invest. Ophthalmol. Vis. Sci. 41:1038-44 (2000)	
	38	Stetler-Stevenson, W.G. and Yu, A.E. Semin. Cancer Biol. 11:143-52 (2001)	
	39	Temkin, V. et al., J. Immunol. 169:2662-9 (2002)	
	40	Temkin, V. et al., Cytokine 24: 74-80 (2003)	

			1	
Exam	ner	Da	ate	
Signa	ıre	Co	onsidered	j

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

							$\overline{}$	
•	Substitute f	or form 1449B/PTO			Complete if Known			
					Application Number	10/789,428		
		RMATION DI			Filing Date	February 27, 2004		
	STATEMENT BY APPLICANT				First Named Inventor	Israel VLODAVSKY		
					Art Unit	1614		
(Use as many sheets as necessary)			y)	Examiner Name		· · · · · · · · ·		
$\overline{\ }$	Sheet	6	of	7	Attorney Docket Number	7640-X04-017		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	41	Thomas, L.L. et al., Immunol. Lett. 78:175-81 (2001)		
	42	Vlodavsky, I, et al., Cancer Res. 43:2704-2711 (1983)		
	43	Vlodavsky, I. et al., Isr, J, Med. 24:464-470 (1988)		
	44	Vlodavsky, I. et al., Trends Biochem. Sci. 16:268-71. (1991)		
	45	Vlodavsky, I. et al., invasion & Metastasis 12:112-127 (1992)		
	46	Vlodavsky, I. et al., Invasion Metastasis 14:290-302 (1994)		
	47	Vlodavsky, I. et al., Tumor Angiogenesis. Eds. C. E. Lewis, R. Bicknell & N. Ferrara. Oxford Uni		
	48	Vlodaysky, I. et al., Nat. Med. 5:793-802 (1999a)		
	49	Vlodaysky, I. et at., Current Protocols in Cell Biology. Vol 1. New York, NY: John Wiley & Sons		
	50	Vlodavsky, I. and Friedmann, J. Clin. Invest. 108:341-7 (2001)		

1			
ı	Examiner	Date	
l	Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known **Application Number** 10/789,428 INFORMATION DISCLOSURE Filing Date February 27, 2004 STATEMENT BY APPLICANT **First Named Inventor** israel VLODAVSKY Art Unit 1614 (Use as many sheets as necessary) **Examiner Name** Sheet Attorney Docket Number 7640-X04-017

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	51	White, R. et al., J. Immunol. Methods 44: 257-63 (1991) (Abstract only)	
	52	Zetser et al., Can. Res. 63:7733-7741 (2003)	
•••••••••••••••••••••••••••••••••••••••	••••••		
•••••••••••			
•••••••••••			
••••••••			
***************************************			
••••••			
			<u>L</u>
Examiner Signature		Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.